BioVie Inc. (BIVI)

Market Cap	29.92M
Revenue (ttm)	n/a
Net Income (ttm)	-37.18M
Shares Out	61.02M
EPS (ttm)	-0.94
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	209,934
Open	0.491
Previous Close	0.499
Day's Range	0.488 - 0.500
52-Week Range	0.445 - 7.633
Beta	1.22
Analysts	Buy
Price Target	8.00 (+1,526.68%)
Earnings Date	May 14, 2024

About BIVI

BioVie Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer'...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2013
• Employees: 18
• Stock Exchange: NASDAQ
• Ticker Symbol: BIVI

Analyst Forecast

According to 2 analysts, the average rating for BIVI stock is "Buy." The 12-month stock price forecast is $8.0, which is an increase of 1,526.68% from the latest price.

Price Target

$8.0

(1,526.68% upside)

Analyst Consensus: Buy